[Other] Safety and efficacy of the anti-汐-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial

medinerdi Post time 1 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-06-15 19:19
Reward10points


Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Junior Member
  • post

  • reply

  • points

    10


Daily Top Contributors

Return to the list